申请人:Hebei Medfaith Pharmaceutical Technology Co., Ltd.
公开号:US10933038B2
公开(公告)日:2021-03-02
The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
本发明属于医药技术领域。特别是,本发明涉及(苯磺酰胺基)苯甲酰胺化合物用于抑制肝纤维化,或预防和/或治疗肝损伤,或改善肝功能,或预防和/或治疗与肝纤维化相关的肝病,用于调节(如减少)肝组织中胶原蛋白(如 I 型胶原蛋白)的含量,用于调节(如抑制)胶原蛋白 A1 的活性。如降低肝组织中胶原蛋白(如 I 型胶原蛋白)的含量,调节(如抑制)细胞中 COL1A1 启动子的活性,调节(如抑制)细胞中与肝纤维化相关基因的表达水平。